ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was the target of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 8,780,000 shares, an increase of 5.0% from the June 30th total of 8,360,000 shares. Based on an average trading volume of 1,540,000 shares, […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) released its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.13, Briefing.com reports. ACADIA Pharmaceuticals had a negative net margin of 28.05% and a negative return on equity of 35.70%. The company had revenue of […]
DNB Asset Management AS bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 12,141 shares of the biopharmaceutical company’s stock, valued at approximately $291,000. A number of other […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its price target lifted by JPMorgan Chase & Co. from $21.00 to $28.00 in a research report released on Monday morning, FlyOnTheWall reports. Other research analysts have also recently issued reports about the stock. Royal Bank of Canada lifted their price target on shares of ACADIA Pharmaceuticals from […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) had its target price increased by Cantor Fitzgerald from $36.00 to $42.00 in a research note released on Monday morning, FlyOnTheWall reports. Cantor Fitzgerald also issued estimates for ACADIA Pharmaceuticals’ FY2023 earnings at ($0.32) EPS and FY2024 earnings at $0.60 EPS. Several other equities analysts also recently commented on […]